Search Bar & Filters
Found 14 Actively Recruiting clinical trials
Actively Recruiting
Women living with HIV WLWH are more likely to develop persistent HPV infection and cervical cancer CC. Effective screening and treatment of pre-cancerous cervical abnormalities are critical to reduce the burden of cervical cancer, especially in sub-Saharan Africa where most WLWH live and resources are limited. This research aims to compare two treatment methods, thermal ablation TA and loop electrosurgical excision procedure LEEP, to determine which is more effective in treating cervical pre-cancerous lesions CIN 23 and HPV infection, and to identify factors linked to treatment failure. The study randomly assigns WLWH who test positive on cervical screening to receive either TA or LEEP. TA uses heat to destroy abnormal cervical tissue and is performed immediately after taking biopsies and curettage if needed. LEEP involves removing cervical tissue and is done following standard procedures, usually without prior biopsies. The study also evaluates pain and side effects related to each treatment and aims to develop an automated tool to predict treatment failure. Participants will undergo assessments including biopsies, colposcopy, and endocervical curettage as needed. Researchers will monitor treatment success at 12 months by comparing cure rates of CIN 23 lesions between the two methods. Safety, side effects, and pain are also tracked. The trial runs until December 2027 and is conducted by Instituto Nacional de Sade, Mozambique, focusing on women aged 25 to 49 living with HIV.
Actively Recruiting
Researchers are evaluating doravirine as an alternative to dolutegravir in people newly diagnosed with HIV-1 infection who have not yet received treatment. This Phase III, open-label, randomized clinical trial aims to determine if doravirine combined with tenofovir and lamivudine is not less effective than dolutegravir combined with tenofovir and lamivudine or emtricitabine. The study will be conducted across multiple countries including Brazil, Cameroon, Cte dIvoire, France, Mozambique, and Thailand, enrolling 610 participants. Participants will be randomly assigned to one of two groups one receiving doravirine 100 mg plus tenofovir DF 300 mg and lamivudine 300 mg daily, and the other receiving dolutegravir 50 mg plus tenofovir DF 300 mg and either lamivudine or emtricitabine daily. The treatment period will last for 96 weeks after starting antiretroviral therapy ART, with primary assessment at week 48 to measure viral suppression. During the study, participants will undergo evaluations to monitor viral load, drug resistance, metabolic health, body weight changes, liver and kidney function, cardiovascular status, and mental health. Adherence to ART will be tracked, and blood samples will be taken to measure drug levels and immune cell counts. The research team will review virological efficacy and safety outcomes at weeks 48 and 96, supporting a comprehensive understanding of the treatments effects over nearly two years of participation.
Actively Recruiting
This research aims to evaluate the Foley Balloon technique combined with misoprostol for preparing the cervix before second trimester surgical abortion between 16 and 21 weeks gestational age. The study compares this method to the standard use of osmotic dilators Laminaria to assess if the Foley Balloon and misoprostol approach is not worse than the usual method. Additionally, the study will explore patient and provider satisfaction with both cervical preparation methods. Participants are randomly assigned to one of two groups. One group will receive a Foley Balloon catheter placed trans-cervically, inflated with saline, along with buccal misoprostol. The other group will have Laminaria devices placed in the cervix according to gestational age. Cervical preparation typically occurs on the first day, followed by dilation and evacuation D&E on the second day to complete the abortion procedure. Participants will undergo the cervical preparation procedure followed by D&E, with assessments including total procedure time, operative time, cervical dilation, complication rates, and pain levels. Satisfaction questionnaires will be completed by both patients and providers. The study spans the preparation and procedure days, with monitoring for safety and effectiveness outcomes. The total procedure time will be about 15-20 minutes during D&E completion, while complications and satisfaction are evaluated over 1-2 days.
Actively Recruiting
Researchers are investigating how a rapid bedside test measuring the biomarker sTREM-1 can identify hospitalized children at higher risk of serious health problems or death in low and middle-income countries. This study aims to see if this test can help guide treatment and improve survival and health after discharge. The trial is part of a larger project focused on improving outcomes for children with fever syndromes. The study involves children aged 1 month to under 5 years who are admitted to hospital and identified as moderate to high risk by the biomarker test. Participants are randomly assigned to receive either L-citrulline syrup, a supplement involved in nitric oxide production, or a placebo. The treatment is given twice daily by weight for 28 days. The trial is conducted in multiple sites in Mozambique and Ethiopia and uses a double-blind, placebo-controlled design. Participants will be followed for six months with visits at the hospital, home, or by phone on days 3, 5, 7, 28, and at 6 months. Researchers will monitor adverse outcomes including death, neurological problems, kidney events, organ support needs, shock, coma, respiratory distress, or hospital readmission within 28 days. Safety events and longer-term health after discharge will also be assessed to understand the treatments impact and overall child survival.
Actively Recruiting
Researchers are studying the management of drug resistance in people living with HIV who are on dolutegravir DTG-based antiretroviral therapy but experience treatment failure due to drug-resistant mutations. This phase 3b randomized clinical trial aims to compare the effectiveness and safety of continuing DTG versus switching to ritonavir-boosted darunavir DRVr in patients with HIV-1 RNA levels above 200 copiesmL and at least one major DTG-associated drug resistance mutation. The study addresses gaps in current treatment strategies across several countries. Participants will be randomly assigned to one of two groups one will continue their existing DTG-based ART regimen, and the other will switch to a DRVr-based ART regimen. The dosing will be based on weight, and the study will take place over 12 months at multiple sites in Kenya, Mozambique, Tanzania, and Lesotho. The primary measure is the proportion of participants achieving viral suppression with HIV-1 RNA below 200 copiesmL at 6 months. During the trial, participants will have regular monitoring of their viral load and drug resistance mutations, along with assessments of treatment adherence, safety, and patient satisfaction. Additional outcomes include viral suppression rates at 12 months, incidence of adverse events, and changes in CD4 counts. The study includes children aged 3 years and older and plans to enroll 392 participants. Follow-up and data collection will support understanding optimal treatment management for this population.
Actively Recruiting
Researchers are investigating new treatment options for adults with newly diagnosed, drug-sensitive pulmonary tuberculosis through a phase 2BC open-label platform study. The trial compares several experimental drug regimens with a standard control treatment to assess efficacy and safety. Participants include adults aged 18 to 65 years with confirmed pulmonary tuberculosis sensitive to rifampicin and isoniazid. The study aims to optimize doses of existing drugs and introduce new medications to improve treatment outcomes. The study is divided into three stages. In stage 1, participants are randomly assigned to the control or one of two experimental arms containing high-dose rifampicin and other drugs for 12 to 17 weeks. Stage 2 adds an experimental arm including the drug BTZ-043, with participants allocated across four arms in varying ratios. Stage 3 begins after stages 1 and 2 complete enrollment, comparing the control arm with two new experimental arms involving novel drug combinations. Treatments are given once daily, with dosages adjusted by arm and weight. Participants will undergo sputum testing, chest X-rays, and molecular tests to confirm tuberculosis and drug sensitivity before enrollment. During the study, researchers will monitor participants through regular clinical assessments, laboratory tests, and electrocardiograms to track treatment response and safety. The main outcomes measured include time to stable culture conversion and changes in mycobacterial load. Safety is evaluated by recording adverse events and laboratory abnormalities over the treatment period, with follow-up continuing up to 12 months after randomization.
Actively Recruiting
Healthy Volunteer
Group B Streptococcus GBS is a leading cause of sepsis and bacterial meningitis in newborns during the first 90 days of life, contributing significantly to newborn deaths. Researchers are preparing for maternal GBS vaccine trials in Africa to improve infection prevention through better data collection, surveillance, and vaccine confidence. The PROTECT project supports sites in Kenya, Malawi, Mozambique, and Uganda to establish uniform pregnancy and infant health data, monitor GBS incidence, and understand factors affecting vaccine acceptance. The study consists of three main parts creating pregnancy exposure registries using electronic health records to track pregnancy and infant outcomes conducting a prospective observational GBS surveillance study among infants under 90 days with confirmed GBS infection at sentinel sites and assessing vaccine confidence through surveys and interviews with pregnant women, healthcare workers, and community leaders. These activities aim to strengthen healthcare systems for future vaccine trials and rollout. Participants include pregnant women and their infants up to hospital discharge for the registry infants under 90 days with confirmed GBS infection for surveillance and pregnant women, healthcare workers, and community stakeholders for vaccine confidence research. The study involves collecting and analyzing medical records, microbiological data, and survey responses over periods ranging from 12 months to two years. Researchers will monitor pregnancy and infant outcomes, GBS infection rates, and vaccine knowledge to prepare for vaccine safety monitoring and effective vaccine implementation.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating new, faster, and simpler tests to diagnose tuberculosis TB in children under 15 years old. These studies, named Rapid Research in Diagnostics Development for TB Network R2D2 Kids and Assessing Diagnostics at Point-of-care for Tuberculosis in Children ADAPT for Kids, aim to reduce childhood TB deaths by improving diagnosis. The challenge lies in collecting sputum samples from children and the low bacteria levels in these samples, which causes delays in diagnosis and treatment. The studies will assess several novel point-of-care TB diagnostic tests including oral swab molecular testing, automated cough sound analysis, automated lung sound analysis with a digital stethoscope, and chest X-ray computer-aided detection using artificial intelligence. These tests are being evaluated for their ability to quickly and accurately detect TB without invasive sputum collection. The studies will enroll children suspected of TB and health workers to also assess the usability and acceptability of these new diagnostic tools. Participants will be children presenting with symptoms or risk factors for TB and will undergo these new diagnostic tests. Researchers will measure the proportion of positive and negative test results compared to standard TB definitions over two years. Usability will be assessed through observations and surveys of health workers. The study will monitor participants over time to evaluate the accuracy and practicality of the tests, with the goal of making TB diagnosis easier and faster in children worldwide.
Actively Recruiting
Researchers are evaluating whether taking azithromycin as a preventive treatment can reduce the risk of death in adults with advanced HIV disease. This is a Phase 3, double-blind, placebo-controlled trial involving multiple centers. The study aims to understand if azithromycin prophylaxis can lower mortality compared to a placebo in this vulnerable population. Participants will be randomly assigned to receive either an oral azithromycin tablet or a matching placebo tablet once daily for 28 days. After this treatment period, they will be followed for 24 weeks to measure the main outcome of all-cause mortality. The total study participation will last 48 weeks to monitor both short-term and longer-term effects. During the study, participants will undergo assessments to track survival and hospitalizations at 12 and 24 weeks after starting the treatment. Researchers will closely monitor health outcomes and any hospital stays to evaluate the impact of azithromycin prophylaxis. Safety and adherence will be followed throughout the trial to ensure accurate measurement of results.
Actively Recruiting
The RIC-AFRICA trial is a multi-center, sham-controlled, randomized controlled trial involving 1400 patients who have experienced ST-segment elevation myocardial infarction STEMI within 24 hours of symptom onset. The study aims to find out if Remote Ischaemic Conditioning RIC can reduce death rates and early heart failure after a heart attack in patients mainly treated with clot-busting therapy. It also includes an observational group of patients presenting between 24 and 72 hours after the heart attack to study similar outcomes without treatment intervention. Participants are randomly assigned to either the RIC group or a sham control group. Those in the RIC group will receive four cycles of blood pressure cuff inflation to 20 mmHg above their systolic blood pressure for 5 minutes, followed by 5 minutes of deflation, repeated four times, and this protocol will be repeated daily for two more days. The sham group will undergo the same cycle with low-pressure inflation to 20 mmHg. The observational group, who present later, will not receive intervention but will be followed with the same outcome measures. Throughout the study, participants will be monitored for all-cause death and new onset heart failure within 30 days after the heart attack. Assessments will include clinical evaluations, ECG, biomarkers, and echocardiography to confirm STEMI and heart function. The study will also track major adverse cardiac and cerebrovascular events at 30 days. The total participation duration varies based on the group, with interventions over three days for the randomized groups and observation for up to 72 hours for the non-randomized group.
1-10 of 14
1